All In Biotech

Drug Trial Radar · NCT02713893

Tolerability and Pharmacokinetic Study of Econazole Nitrate and Benzydamine HCl Intravaginal Cream

A Phase I Study of a Novel Intravaginal Antimycotic Cream (Econazole Nitrate 1% Plus Benzydamine HCl 0.12%) Administered Once Daily for 15 Days to Healthy Women

Last checked: Nov 19, 2026Latest source record: Jan 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Sep 2015

Primary completion

Jun 2016

Study completion Jun 15, 2016

Sponsor

Sponsor type
Industry
Collaborators
Cross Research S.A.
First posted
Mar 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate local tolerability of the new Econazole/Benzydamine product, in comparison with the Econazole and Benzydamine stand-alone products and placebo. Pharmacokinetics of the study products after single and repeated applications once a day for 15 days, safety of the investigational products and comfort of use will also be evaluated as secondary objectives.

Conditions

  • Healthy

Interventions

  • Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal creamDrug

  • Placebo plus Econazole nitrate 1% intravaginal creamDrug

  • Placebo plus Benzydamine HCl 0.12% intravaginal creamDrug

  • Placebo intravaginal creamDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Local Adverse Events (AEs)Time frame: Up to 7 days after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CROSS Research S.A., Phase I Unit

    Arzo, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.